GFAP and S100B are biomarkers of traumatic brain injury
Top Cited Papers
- 16 November 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 75 (20), 1786-1793
- https://doi.org/10.1212/wnl.0b013e3181fd62d2
Abstract
Background: Biomarker levels in blood after traumatic brain injury (TBI) may offer diagnostic and prognostic tools in addition to clinical indices. This study aims to validate glial fibrillary acidic protein (GFAP) and S100B concentrations in blood as outcome predictors of TBI using cutoff levels of 1.5 μg/L for GFAP and 1.13 μg/L for S100B from a previous study. Methods: In 79 patients with TBI (Glasgow Coma Scale score [GCS] ≤12), serum, taken at hospital admission, was analyzed for GFAP and S100B. Data collected included injury mechanism, age, gender, mass lesion on CT, GCS, pupillary reactions, Injury Severity Score (ISS), presence of hypoxia, and hypotension. Outcome was assessed, using the Glasgow Outcome Scale Extended (dichotomized in death vs alive and unfavorable vs favorable), 6 months post injury. Results: In patients who died compared to alive patients, median serum levels were increased: GFAP 33.4-fold and S100B 2.1-fold. In unfavorable compared to favorable outcome, GFAP was increased 19.8-fold and S100B 2.1-fold. Univariate logistic regression analysis revealed that mass lesion, GFAP, absent pupils, age, and ISS, but not GCS, hypotension, or hypoxia, predicted death and unfavorable outcome. Multivariable analysis showed that models containing mass lesion, pupils, GFAP, and S100B were the strongest in predicting death and unfavorable outcome. S100B was the strongest single predictor of unfavorable outcome with 100% discrimination. Conclusion: This study confirms that GFAP and S100B levels in serum are adjuncts to the assessment of brain damage after TBI and may enhance prognostication when combined with clinical variables.Keywords
This publication has 35 references indexed in Scilit:
- Predicting Outcome after Traumatic Brain Injury: Development and International Validation of Prognostic Scores Based on Admission CharacteristicsPLoS Medicine, 2008
- Classification of Traumatic Brain Injury for Targeted TherapiesJournal of Neurotrauma, 2008
- Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patientsBMJ, 2008
- Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injuryActa Neurochirurgica, 2008
- Protein S-100 and neuropsychological functioning following severe traumatic brain injuryBrain Injury, 2006
- GFAP Versus S100B in Serum after Traumatic Brain Injury: Relationship to Brain Damage and OutcomeJournal of Neurotrauma, 2004
- Temporal Profile of Release of Neurobiochemical Markers of Brain Damage After Traumatic Brain Injury Is Associated With Intracranial Pathology as Demonstrated in Cranial Computerized TomographyJournal of Neurotrauma, 2000
- The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre studyBrain Injury, 2000
- The S100 family of EF-hand calcium-binding proteins: functions and pathologyTrends in Biochemical Sciences, 1996
- Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injurySurgical Neurology, 1995